

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.elsevier.com/locate/mjafi](http://www.elsevier.com/locate/mjafi)

## Review Article

# Dehydroepiandrosterone: A panacea for the ageing ovary?



Lt Col Nikita Naredi <sup>a,\*</sup>, Lt Col K. Sandeep <sup>b</sup>, Lt Col V.D.S. Jamwal <sup>c</sup>,  
Lt Col N. Nagraj <sup>d</sup>, Lt Col Seema Rai <sup>d</sup>

<sup>a</sup> IVF Specialist, Assisted Reproductive Technology Centre, Army Hospital (R&R), New Delhi 110 010, India

<sup>b</sup> IVF Specialist, Assisted Reproductive Technology Centre, INHS Asvini, Mumbai, India

<sup>c</sup> Graded Specialist (Anatomy), Military Hospital Ahmedabad, Gujarat, India

<sup>d</sup> Senior Resident, Assisted Reproductive Technology Centre, Army Hospital (R&R), New Delhi 110 010, India

## ARTICLE INFO

## Article history:

Received 12 October 2014

Accepted 28 December 2014

Available online 25 February 2015

## Keywords:

Dehydroepiandrosterone

DHEA

Premature ovarian ageing

## ABSTRACT

Considerable improvements and advancements have been made in the treatment of infertility but poor ovarian reserve whether due to prematurely or a physiologically ageing ovary, continues to be one of the few unresolved problems of modern infertility care. Fertility researchers had been active for quite some time to find a way to help reverse the effects of ageing on the ovaries but none made an impact till the introduction of Dehydroepiandrosterone [DHEA]. DHEA a mild, and therapeutically well tolerated, male hormone has emerged as a real potential candidate to reverse the effects of ageing on ovaries. Apart from this, DHEA has also been postulated to improve egg and embryo quality, pregnancy rates and time to conception and reduces miscarriage rates. This review attempts to highlight the mechanism of action of this drug, its indications and its current status for treating women with decreased ovarian reserve.

© 2015, Armed Forces Medical Services (AFMS). All rights reserved.

## Introduction

Menopause, the culmination of a woman's reproductive life, occurs when women experience a dramatic loss in ovarian function around the age of 50.<sup>1</sup> It is a consequence of the age-related decrease in the follicle number which dictates the onset of cycle irregularity and the final cessation of menses. This final occurrence of natural sterility is preceded by a process known as "Ovarian Ageing" in which there is a parallel decay in both the quantity and the quality of oocytes.<sup>2</sup> However in approximately 10% of women the decline of ovarian function occurs much earlier than others because of a phenomenon called premature ovarian ageing [POA].<sup>3</sup>

The follicular pool of the ovary of a woman, which she is endowed with is known as ovarian reserve [OR] and the ovarian reserve keeps declining with advancing female age. A good OR gives a lady the ability to produce high-quality eggs and thus achieve pregnancy. When this ovarian reserve becomes low or poor relative to what is expected at any given age it is known as premature ovarian ageing.<sup>2</sup> POA was one of the major often overlooked causes of female infertility.

Fertility researchers were thus active for quite some time to find a method to help reverse the effects of ageing on the ovaries and help women with poor ovarian reserve. Many drugs made their appearance in the arena of reproductive medicine to resolve the issue of physiologically and prematurely ageing ovaries but none made an impact till 2000.

\* Corresponding author. Tel.: +91 (0) 8800504222 (mobile).

E-mail address: [nikitanaredi@gmail.com](mailto:nikitanaredi@gmail.com) (N. Naredi).

<http://dx.doi.org/10.1016/j.mjafi.2014.12.022>

0377-1237/© 2015, Armed Forces Medical Services (AFMS). All rights reserved.

Casson et al first reported the beneficial effects of dehydroepiandrosterone [DHEA] on ovaries with diminished reserve.<sup>4</sup> They reported that DHEA supplementation of women with diminished ovarian reserve [DOR] may bring about a positive impact on ovarian function by increasing the oocyte yield after stimulation with gonadotropins. Thereafter, since the beginning of this decade this drug is being administered at various Fertility centres to overcome the challenge of poor ovarian reserve in both, the ageing population of sub fertile women and the poorly responding young women.

---

### What is DHEA?

Dehydroepiandrosterone [DHEA] and dehydroepiandrosterone sulphate [DHEA-S] are natural steroid hormones, which are the major secretory products primarily from the zona reticularis of the human adrenal cortex and to a lesser extent from the ovarian theca cells.<sup>4</sup> These hormones circulate in high amounts during female reproductive life however, concentrations fall progressively with age.<sup>5</sup> The age-related decrease in DHEA secretion inevitably raised the question that if ageing is a consequence of DHEA deficiency, it could be reversed by DHEA treatment.<sup>6</sup>

---

### How does DHEA act?

Dehydroepiandrosterone is an essential prohormone in ovarian follicular steroidogenesis<sup>4</sup> during the conversion of cholesterol to the two sex hormones, oestradiol and testosterone.<sup>7</sup> Another plausible mechanism postulated for the gonadotropin-augmentation effect secondary to DHEA supplementation is that it enhances the serum free IGF-I concentrations by ~150%, independently of changes in GH secretion.<sup>8,9</sup> Thus DHEA amplifies hepatic and end organ IGF-I response to GH which in the milieu of the ovarian follicle, may potentiate gonadotropin action.

Anti-Mullerian Hormone [AMH] an indicator of ovarian reserve is a dimeric glycoprotein and a member of the transforming growth factor super family. It is exclusively produced by the granulosa cells of early developing follicles from primary to antral follicle stages 10. Improvement in AMH concentrations as revealed by Gleicher et al suggested that DHEA increases the pool of follicles up to pre-antral stage.<sup>3</sup> This observation added to another of the possible mechanisms by which DHEA exerts its effects: it affects recruitment from the dormant primordial follicular pool, may reduce apoptosis which is the primary process of elimination for originally recruited follicles or may selectively and directly affect granulosa cells.<sup>10</sup>

---

### Who would be benefitted?

The indications for institution of DHEA supplementation has progressively changed since its first use in 2004 by The Centre for Human Reproduction [CHR] in New York City, the torch bearers in the usage of this wonder drug till date.<sup>4,7,11,12</sup> Initially only older women above age 42 were supplemented with a prerequisite of one failed IVF cycle and retrieval of less than 4

oocytes. By mid-2005 DHEA was instituted to all women above age 40 with evidence of poor ovarian reserve and a history of one failed prior IVF cycle. By early 2006 indications were further extended to women under age 40 if they demonstrated elevated baseline follicle stimulating hormone [FSH] levels above 10 mIU/ml and had shown ovarian resistance in at least one failed IVF cycle. After mid-2006 FSH baseline criteria was changed from absolute FSH elevations to elevations in age-specific FSH levels.<sup>13</sup> At present all women above age 40 are being offered routine supplementation in many centres since January 2007, while younger women under age 40 are continuing to be only selectively supplemented if demonstrating elevated age-specific baseline FSH levels and have had inappropriately low oocyte yield in at least one IVF cycle.<sup>2</sup>

---

### How much and for how long?

DHEA supplementation is carried out with oral, pharmaceutical grade micronized medication at a dosage of 25 mg, three times daily. The morbidly obese women require a daily dosage of 100 mg. This supplementation dosage was adopted in practice since it represented the amount of medication the index patient had used, as inspired by the report by Casson et al<sup>4,11</sup> and has therefore remained the only standard treatment dosage. Patients should receive at least two months of DHEA supplementation prior to oocyte retrieval however maximal DHEA effects increases over time, reaching peaks after approximately four to five months of supplementation.<sup>14</sup> Women may conceive spontaneously while on DHEA<sup>7</sup> in which case, it is discontinued after confirmation of pregnancy by the second positive pregnancy test.

---

### How to monitor DHEA effect?

Ovarian reserve has traditionally been measured by FSH concentrations on cycle days 2 or 3<sup>13</sup> but of late Anti-Mullerian hormone [AMH] has attracted more attention and has, been suggested as a more specific reflector of ovarian activity.<sup>13,15</sup> Its utilization for investigation of prematurely diminished ovarian reserve has also been documented.<sup>16</sup> Thus AMH levels may be utilised to assess ovarian reserve following DHEA supplementation.

Gleicher et al in their study for the first time by assessing changes in AMH concentration presented that DHEA supplementation positively affected the diminished ovarian pool with a steady increase in AMH concentration after initiation of DHEA.<sup>3</sup> This DHEA effect was visible not only in older ovaries, but found to be more pronounced in younger women with premature ovarian ageing.

---

### What are the side effects?

Side effects at the dosages being prescribed for DOR are small and rare, and primarily relate to androgen effects. Women using DHEA may experience possible adverse effects like acne, hair loss, deepening of the voice, and facial hair growth however most of them are reversible. DHEA in a dosage of

75 mg/day has been well tolerated by most patients in the various studies and it has been observed that adverse effects are uncommon at a DHEA dose of <100 mg per day<sup>12</sup> More frequently, patients comment on improved energy levels and better sex drive while they are on this drug.<sup>12,17</sup>

### Is DHEA really a miracle drug?

Poor ovarian reserve and ovarian ageing posed a big challenge to the infertility experts and thus the discovery of a drug which could circumvent this obstacle was considered a great breakthrough. Therefore a great hype had been created in the IVF world since a decade, about Dehydroepiandrosterone [DHEA] supplementation for improving ovarian reserve in women of advanced age or prematurely ageing ovaries or those responding poorly to gonadotropin stimulation. Few studies definitely documented that DHEA supplementation for at least 3 months was associated with spontaneous and treatment-induced pregnancies in women with very high FSH or very low Anti-Mullerian hormone [AMH] levels.<sup>3,18</sup> AMH which reflects the total quantity and possibly quality of the remaining follicular pool and a marker of declining reproductive age<sup>19</sup> was also found to be steadily improved in patients with diminished ovarian reserve after 90–120 days of post DHEA initiation.<sup>3</sup> DHEA was also labelled the first medication which by improving the ovarian microenvironment returned it to a 'younger' functionality, leading to a yield of better quality eggs and embryos, higher pregnancy and lower miscarriage rates.<sup>13,14</sup> In another study by Gleicher's group it was seen that there was a lower rate of embryonic aneuploidy in the DHEA group as detected by preimplantation genetic screening.<sup>20</sup>

### DHEA: Hype or hope?

Dehydroepiandrosterone [DHEA] was brought in as a 'cure all-drug' for the ageing ovary and treatment of poor responders to controlled ovarian hyperstimulation, but many researchers have been questioning its actual effectiveness. Yakin and his associates were doubtful about the role of DHEA in DOR and considered its supplementation as experimental.<sup>21</sup>

Despite the controversy the use of DHEA in women to enhance the ovarian reserve has been supported by retrospective analyses<sup>3</sup> prospective self-controlled studies,<sup>4,12,20</sup> and case-control studies.<sup>13,14</sup> Wisner et al in his only randomized controlled trial also concluded a better pregnancy rate and a statistically significant live birth rate after DHEA institution.<sup>22</sup> Therefore DHEA may be administered to woman with DOR who have suffered one unsuccessful attempt at ovarian stimulation and the response to be monitored with improving AMH concentrations.

### Conclusion

Dehydroepiandrosterone supplementation although in vogue for almost a decade for its proposed beneficial effect on women with poor ovarian reserve as well as poor responders

to gonadotropins during ovarian stimulation, its usage has been surrounded by lot of controversy.

Nevertheless it has shown demonstrable benefits in terms of better oocyte yield, better oocyte and embryo quality and an increase in the Anti-Mullerian hormone levels. Thus this drug may be considered for poor responders and in women with physiologically and prematurely ageing ovaries due to its simplicity of use and lack of significant side effects. However large-scale well-designed confirmatory studies are necessary to prove the efficacy of DHEA before it can be recommended for routine use and be considered an elixir for the ageing ovaries.

### Conflicts of interest

All authors have none to declare.

### REFERENCES

1. Treloar AE. Menstrual cyclicity and the pre-menopause. *Maturitas*. 1981;3:49–64.
2. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. *Endocr Rev*. 2009;30:465–493.
3. Gleicher Norbert, Weghofer Andrea, Barad David H. Improvement in ovarian reserve. *Reprod Biomed Online*. 2010;2:360–365.
4. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. *Hum Reprod*. 2000;15:129–132.
5. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Clin Endocrinol Metab*. 1984;59:551–555.
6. Casson PR, Carson SA, Buster JE, et al. Replacement dehydroepiandrosterone in elderly: rationale and prospects for the future. *Endocrinologist*. 1998;8:187–194.
7. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. *J Assist Reprod Genet*. 2007;24:629–634.
8. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SSC. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone [DHEA] on circulating sex steroids, body composition and muscle strength in age-advanced men and women. *Clin Endocrinol*. 1998;49:421–432.
9. Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high density lipoprotein: a six-month trial. *Fertil Steril*. 1998;70:107–110.
10. Krysko DV, Diez-Fraile A, Criel G, Svistunov AA, Vandenebeele P, D'Herde K. Life and death of female gametes during oogenesis and folliculogenesis. *Apoptosis*. 2008;13:1065–1087.
11. Barad D, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. *Fertil Steril*. 2005;84:756e1–756e3.
12. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. *Hum Reprod*. 2006;21:2845–2849.

13. Barad DH, Weghofer A, Gleicher N. Age-specific levels of basal follicle stimulating hormone assessment of ovarian function. *Obstet Gynecol.* 2007a;109:1404–1410.
14. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Dehydroepiandrosterone [DHEA] reduces miscarriage rates in women with diminished ovarian reserve: a multicenter study. *Reprod Biol Endocrinol.* 2009;7:108.
15. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Antimüllerian hormone as marker of ovarian reserve. *Aust N Z J Obstet Gynaecol.* 2005;45:20–24.
16. Rohr J, Allen EG, Charen K, et al. Anti-Müllerian hormone indicates early ovarian decline in fragile X mental retardation [FMR1] permutation carriers: a preliminary study. *Hum Reprod.* 2008;23:1220–1225.
17. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). *Reprod Biol Endocrinol.* 2011;9:67.
18. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. *Fertil Steril.* 2009a;91:644–646.
19. La Marca A, Volpe A. Anti-Müllerian hormone [AMH] in female reproduction: is measurement of circulating AMH a useful tool? *Clin Endocrinol [Oxf].* 2006;64:603–610.
20. Gleicher Norbert, Weghofer Andrea, Barad David H. Dehydroepiandrosterone [DHEA] reduces embryo aneuploidy: direct evidence from preimplantation genetic screening [PGS]. *Reprod Biol Endocrinol.* 2010;8:140.
21. Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope? *Hum Reprod.* 2011;26:1941–1944.
22. Wisner A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone [DHEA] for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. *Hum Reprod.* 2010;25:2496–2500.